Subgroups
Outcomes (7)
- immune-mast-cell-activation-syndrome-symptom-benefit-rate-89-percent-self-reported
- immune-mast-cell-activation-syndrome-symptom-dramatic-relief-self-reported
- immune-mast-cell-activation-syndrome-symptom-improvement-self-reported
- immune-mast-cell-activation-syndrome-symptom-normalization-next-day-self-reported
- immune-mast-cell-activation-syndrome-symptom-remission-no-issues-self-reported
- immune-mast-cell-activation-syndrome-symptom-remission-two-years-self-reported
- immune-mast-cell-activation-syndrome-symptom-severity-decrease-60-to-90-percent-self-reported
Protocols & scoring
diet-gaps-nervous-system-regulation-exercises1 evidence row
| Outcome | Effect | Confidence | N |
|---|---|---|---|
| immune-mast-cell-activation-syndrome-symptom-improvement-self-reported | +15 | 15 | 1 |
diet-low-histamine-cetirizine-treatment1 evidence row
| Outcome | Effect | Confidence | N |
|---|---|---|---|
| immune-mast-cell-activation-syndrome-symptom-improvement-self-reported | +10 | 10 | 1 |
lifestyle-relocation-back-to-birthplace1 evidence row
| Outcome | Effect | Confidence | N |
|---|---|---|---|
| immune-mast-cell-activation-syndrome-symptom-remission-two-years-self-reported | +40 | 20 | 1 |
lifestyle-relocation-to-desert1 evidence row
| Outcome | Effect | Confidence | N |
|---|---|---|---|
| immune-mast-cell-activation-syndrome-symptom-remission-no-issues-self-reported | +45 | 20 | 1 |
lifestyle-travel-desert-trip-four-hour-drive1 evidence row
| Outcome | Effect | Confidence | N |
|---|---|---|---|
| immune-mast-cell-activation-syndrome-symptom-normalization-next-day-self-reported | +50 | 25 | 1 |
lifestyle-travel-one-week-alaska-winter1 evidence row
| Outcome | Effect | Confidence | N |
|---|---|---|---|
| immune-mast-cell-activation-syndrome-symptom-dramatic-relief-self-reported | +55 | 25 | 1 |
medication-diabetes-glp-one-receptor-agonist-treatment1 evidence row
| Outcome | Effect | Confidence | N |
|---|---|---|---|
| immune-mast-cell-activation-syndrome-symptom-benefit-rate-89-percent-self-reported | +89 | 40 | 47 |
medication-diabetes-tirzepatide-microdosing1 evidence row
| Outcome | Effect | Confidence | N |
|---|---|---|---|
| immune-mast-cell-activation-syndrome-symptom-severity-decrease-60-to-90-percent-self-reported | +75 | 40 | 350 |
Path: immune › mast › cell › activation › syndrome › symptom